Orchestra BioMed Q2 Revenue Plunges, Loss Widens to $24.1M
OBIO has more than doubled off its 52-week low of $2.2.
Summary
Orchestra BioMed's Q2 revenue dropped sharply with minimal product and partnership sales, while net loss widened to $24.1 million ($0.38 per share) driven by higher R&D spending on pivotal trials. The company ended the quarter with $110 million in cash after a $35 million strategic investment from Medtronic and Ligand, extending its runway into Q4 2027. Management expects to complete enrollment in the BACKBEAT trial by end of Q3 2026, with primary data targeted for Q2 2027. The results underscore the pre-revenue biotech's heavy reliance on external funding to advance its pipeline, though the strengthened balance sheet reduces near-term dilution risk.
At the time of this announcement, OBIO was trading at $4.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $267.1M. The 52-week trading range was $2.20 to $5.42. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.